We use cookies to so our web site can function correctly. By Clicking "OK" or by clicking into any content on this site, you agree to allow cookies to be placed. To find out more visit the cookies section of our privacy policy.

Privacy Statement

A cookie is a small file which asks permission to be placed on your computer's hard drive. Once you agree, the file is added and the cookie helps analyse web traffic or lets you know when you visit a particular site. Cookies allow web applications to respond to you as an individual. The web application can tailor its operations to your needs, likes and dislikes by gathering and remembering information about your preferences.

We use traffic log cookies to identify which pages are being used. This helps us analyse data about web page traffic and improve our website in order to tailor it to customer needs. We only use this information for statistical analysis purposes.

Overall, cookies help us provide you with a better website, by enabling us to monitor which pages you find useful and which you do not. A cookie in no way gives us access to your computer or any information about you, other than the data you choose to share with us.

Cookie group mandatory

(Req)
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms.
You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

These cookies are required

Functional

These cookies allow us to adtertise our products to you and allow us to pass this information on to our trusted third parties so that they can advertise our products to you on our behalf
All information these cookies collect is aggregated and therefore anonymous. No personal inforation is shared to third parties. Any personal information collected while using our website could be used for direct marketing from HCA only

Marketing

These cookies allow us to advertise our products to you and allow us to pass this information on to our trusted third parties so that they can advertise our products to you on our behalf
All information these cookies collect is aggregated and therefore anonymous. No personal inforation is shared to third parties. Any personal information collected while using our website could be used for direct marketing from HCA only

Performance Cookies

These cookies allow us to know which pages are the most and least popular and see how visitors move around the site.  All information collect is annonomas unless you provide personal information to us.
If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.

News

April 08, 2019

HCA UK Launch CAR T-Cell Therapy for Cancer Treatment

Dubbed the ‘5th pillar of cancer treatment’, CAR T-cell therapy marks a significant breakthrough in the way certain types of blood cancer can be treated.

APRIL 2019 - HCA Healthcare UK has announced the launch of CAR T-cell therapy - a ground-breaking new blood cancer treatment which will be available to eligible patients with certain types of lymphoma (including diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma and transformed follicular lymphoma), before being introduced for patients with other blood cancers in the coming months.  

CAR T-cell therapy is a complex treatment and will only be available at a small number of sites in the UK.  Reinforcing their status as one of the UK’s leaders in cancer treatment, HCA Healthcare UK will be one of the few highly specialised centres and among the first private providers to offer patients the latest CAR T-cell therapy in JACIE-IEC accredited units which are rated CQC “Outstanding”.  

This revolutionary treatment will be available at HCA UK at University College Hospital and The Christie Private Care (part of HCA Healthcare UK) from this spring.  

About CAR T-Cell Therapy


CAR T-Cell therapy (Chimeric Antigen Receptor T-cell therapy) is a unique, first of its kind, treatment which uses a patient’s own T-cells to seek and destroy cancer cells – without the use of drugs. Referred to by many as the ‘5th pillar of cancer treatment’ (following surgery, chemotherapy, radiotherapy and targeted therapies), the arrival of CAR T-cell therapy marks a significant step forward in the treatment of blood cancer, bringing renewed hope to both patients and the medical world alike – and offering a glimpse of what treatment could look like for multiple tumour types in the future.

 

T-cells are a type of white blood cell which play a vital role in the immune system. They discover and remove infection from the body (orchestrating an immune response to kill cells which have been infected by pathogens). During this process T-cells use their protein receptors to latch on to antigens found on the surface of other cells and examine them; the T-cell will move on if the examined cell is healthy or release killer chemicals to destroy an infected cell.

 

Cancer has the ability to evade and fool the immune system. It does this by disguising itself as a healthy cell or by creating multiple abnormal antigens on its surface which prevent the T-cell receptors from being able to latch on as they normally would. This disables them from inspecting the cancer cell and identifying it as foreign and dangerous. The cancer is then able to continue to grow and multiply without the essential intervention of the T-cells. CAR T-cell therapy intervenes in this process by modifying T-cells, adding new targeted receptors which enable them to see and destroy cancer cells.

 

To do this, patient’s T-cells are firstly collected in a process which is similar to a blood donation. Blood is removed through an intravenous drip in the patient’s arm and put through an apheresis machine which separates and collects the T-cells from the other blood cells (which are then returned to the body).

 

Next, the separated T-cells are sent to a laboratory where they are genetically altered by adding the Chimeric Antigen Receptors, turning them into ‘CAR T-cells’. These newly engineered cells are then expanded in the lab and millions of them are infused back into the patient following a short course of conditioning chemotherapy. The T-cells new Chimeric Antigen Receptors enable them to latch onto a specific antigen on the patient’s tumour cells and destroy them.

Professor Stephen Mackinnon, one of the UK’s leading experts on Car T-Cell Therapy and Chair of the HCA Healthcare UK Blood Cancer Board says:

CAR T-cell therapy is a complex treatment and will only be available at a small number of sites in the UK. HCA Healthcare UK will be one of the first JACIE-IEC accredited private providers in the UK to offer CAR T-cell therapy. 

Blood cancer is the third biggest cancer killer in the UK however, CAR T-cell therapy is a game-changing treatment for many patients.  So far, some patients who have undergone this treatment have shown a rapid and durable regression and remission that we haven’t observed in other recognised treatments. 

This is a ‘first of a kind’ therapy and is a big moment for the treatment of cancer.  CAR T-cell therapy has the potential to revolutionise the approach to cancer treatment moving forward
.”
 

For more information contact HCAUK@thephagroup.com / 020 7025 1363

About HCA Healthcare UK

HCA UK Launch Revolutionary CAR T-Cell Therapy
back to top